Compare Gilead Sciences, Inc. (GILD) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Yum! Brands, Inc. — how do they compare? Gilead Sciences, Inc. trades at $134 (market cap $163.51B), while Yum! Brands, Inc. trades at $152.08 (market cap $42.05B). The key difference: Gilead Sciences, Inc. is far larger — about 3.9× Yum! Brands, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | YUM | |
|---|---|---|
Market Cap | $163.51B | $42.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $168.16 |
52-Week Low | $108.22 | $138.21 |
Enterprise Value | $178.05B | $53.32B |
Dividend Yield | 2.49% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
YUM Brands trades at $152.32, down 3.73% amid a food safety investigation at Taco Bell. Technical indicators show bearish momentum with support at $151 and resistance at $154. Fundamentally, revenue grew to $8.21B in 2025 with a net income margin of 20.48%, while the P/E ratio stands at 24.61. The company recently announced the $2.7B sale of Pizza Hut to focus on KFC and Taco Bell, alongside a $4B share buyback authorization.
The outlook remains cautious due to near-term headwinds from the health probe, but long-term growth prospects are supported by brand focus and capital returns. Risks include regulatory scrutiny and integration challenges from the divestiture. Analysts maintain a consensus price target of $174.60 with 37% buy ratings, suggesting potential upside if operational stability is restored.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
